Victoza is Novo Nordisk’s once-daily injectable GLP-1 agonist and made around $3.6 billion in sales last year, making it the top-selling drug in the category.

Novo Nordisk has settled a US patent case with Teva, which prevents the Israel-based generics firm marketing a cheaper version of its key type 2 diabetes drug Victoza until 2023.

Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of drugs that are allowed to be compounded. In a Citizen Petition posted on ...

In the early stages of Type 2 diabetics use Metformin, a generic drug, but as the disease progresses Novo Nordisk’s Victoza (liraglutide) becomes very useful since it stimulates the pancreas to ...

Novo Nordisk A/S (NOVO-B.KO) expects its closely-watched diabetes treatment Victoza to reach European customers in the nearest future, Chief Scientific Officer Mads Krogsgaard Thomsen said in an ...

Some in the industry expect it to achieve blockbuster sales, as Victoza has done. Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk, said in December, "Type 2 ...